We are live on ! Find out more
NCM

Nantahala Capital Management Portfolio holdings

AUM $2.72B
1-Year Est. Return 121.58%
This Fund
S&P 500
This Quarter Est. Return
-6.99%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.71B
AUM Growth
-$39.6M
Cap. Flow
+$72.3M
Cap. Flow %
4.23%
Top 10 Hldgs %
57.63%
Holding
146
New
23
Increased
28
Reduced
39
Closed
16

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$28.5M
2
ESTA icon
Establishment Labs
ESTA
+$27.8M
3
PTON icon
Peloton Interactive
PTON
+$16.6M
4
SVRA icon
Savara
SVRA
+$15.3M
5
OPTN
OptiNose
OPTN
+$12.2M

Top Sells

Rank Stock Value
1
CASH icon
Pathward Financial
CASH
+$25.3M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$17.5M
3
RDVT icon
Red Violet
RDVT
+$13.4M
4
DYN icon
Dyne Therapeutics
DYN
+$12.4M
5
GDEN
Golden Entertainment
GDEN
+$9.92M

Sector Composition

Rank Sector Weight
1 Healthcare 39.62%
2 Consumer Discretionary 7%
3 Financials 3.63%
4 Communication Services 3.53%
5 Technology 1.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRON icon
51
Disc Medicine
IRON
$2.99B
$6.76M 0.4%
+150,000
New +$5.1M
ALTG icon
52
Alta Equipment Group
ALTG
$234M
$6.74M 0.39%
838,222
+435,713
+108% +$4.41M
COGT icon
53
Cogent Biosciences
COGT
$7.11B
$6.67M 0.39%
790,936
– –
MLYS icon
54
Mineralys Therapeutics
MLYS
$2.39B
$6.23M 0.36%
532,506
+200,000
+60% +$2.52M
ATXS
55
DELISTED
Astria Therapeutics
ATXS
$6.14M 0.36%
+675,000
New +$6.59M
BNTC icon
56
Benitec Biopharma
BNTC
$464M
$5.88M 0.34%
+841,395
New +$6.21M
EGRX
57
CALL
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$5.6M 0.33%
+1,000,000
New +$4.36M
VTGN icon
58
VistaGen Therapeutics
VTGN
$11.9M
$5.28M 0.31%
1,517,696
– –
STKS icon
59
The ONE Group
STKS
$55.9M
$5.11M 0.3%
1,202,528
+654,818
+120% +$3.4M
NKTR icon
60
Nektar Therapeutics
NKTR
$2.54B
$5.1M 0.3%
274,000
+108,936
+66% +$2.3M
NSPR icon
61
InspireMD
NSPR
$39.5M
$5.06M 0.3%
2,026,600
-39,856
-2% -$93.4K
AVDL
62
DELISTED
Avadel Pharmaceuticals
AVDL
$4.92M 0.29%
+350,000
New +$5.71M
DXPE icon
63
DXP Enterprises
DXPE
$3.02B
$4.73M 0.28%
103,206
-166,600
-62% -$8.41M
NPCE icon
64
Neuropace
NPCE
$502M
$4.66M 0.27%
616,823
-161,437
-21% -$1.63M
RDI icon
65
Reading International Class A
RDI
$35M
$4.61M 0.27%
3,244,573
-140,680
-4% -$230K
CLRB icon
66
Cellectar Biosciences
CLRB
$20.8M
$4.58M 0.27%
61,111
-1,333
-2% -$128K
ZYXI
67
DELISTED
Zynex
ZYXI
$4.57M 0.27%
490,000
– –
NNBR icon
68
NN Inc
NNBR
$309M
$4.37M 0.26%
1,456,446
+50,000
+4% +$175K
DHX icon
69
DHI Group
DHX
$159M
$4.32M 0.25%
2,066,417
+100,000
+5% +$232K
PWP icon
70
Perella Weinberg Partners
PWP
$1.25B
$4.31M 0.25%
265,474
+165,696
+166% +$2.5M
CNTA
71
DELISTED
Centessa Pharmaceuticals
CNTA
$4.06M 0.24%
+450,000
New +$4.27M
GAIA icon
72
Gaia
GAIA
$48.1M
$4.04M 0.24%
915,029
– –
CNTX icon
73
Context Therapeutics
CNTX
$41.9M
$3.88M 0.23%
+1,935,484
New +$3.34M
LXRX icon
74
Lexicon Pharmaceuticals
LXRX
$1.09B
$3.87M 0.23%
+2,304,150
New +$4.13M
SLN
75
Silence Therapeutics
SLN
$729M
$3.8M 0.22%
200,000
– –
1 2
3
4 5

Similar funds

TAM
Timucuan Asset Management Jacksonville, Florida $2.72B AUM 4.95% 1-Year Est. Return
XL
XN LP New York $2.72B AUM 46.67% 1-Year Est. Return
NB
Nicolet Bankshares Green Bay, Wisconsin $2.71B AUM 17.55% 1-Year Est. Return
PA
Profund Advisors Bethesda, Maryland $2.72B AUM 47.27% 1-Year Est. Return
BCM
Bowie Capital Management Richardson, Texas $2.71B AUM 5.42% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
GC
Giverny Capital Montreal, Quebec, Canada $2.73B AUM 14.09% 1-Year Est. Return

Nantahala Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Nantahala Capital Management held 146 positions worth $1.71B, down 2.3% from $1.75B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Nantahala Capital Management deployed $72.3M of net new capital in Q2 2024, opening 23 new positions and adding to 28 existing holdings. Its largest new stake was The Bancorp: 337,846 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 37% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was Pathward Financial, an estimated $25.3M trimmed.

  • Nantahala Capital Management's largest Q2 2024 buy was The Bancorp: 337,846 shares worth $12.8M.
  • Nantahala Capital Management added most to Soleno Therapeutics in Q2 2024, an estimated $28.5M increase.
  • Nantahala Capital Management's biggest Q2 2024 reduction was Pathward Financial, cutting an estimated $25.3M.
  • Nantahala Capital Management fully exited LYRA THERAPEUTICS INC in Q2 2024, selling an estimated $17.5M.
  • Nantahala Capital Management's ten largest holdings make up 58% of its $1.71B portfolio in Q2 2024.
  • Nantahala Capital Management opened 23 new positions and closed 16 in Q2 2024.
  • Nantahala Capital Management's portfolio value fell 2.3% quarter-over-quarter to $1.71B.

Based on Nantahala Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.